Paul Lizotte, DO
Internal Medicine · Oceanside, CANPI 1699855841
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations.
Across 123 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$510
- Lilly USA, LLC$256
- Bayer$203
- Boehringer Ingelheim$131
- Amgen$107
- Merck$104
- plus $1K from 24 others
Across 4 payments — averaging $10,635 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novavax Inc$43K
What the payments were for
- Food & beverage$2,30399%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $510 |
| Lilly USA, LLC | 16 | $256 |
| Bayer | 11 | $203 |
| Boehringer Ingelheim | 7 | $131 |
| Amgen | 5 | $107 |
| Merck | 6 | $104 |
| Exact Sciences | 4 | $103 |
| Pfizer | 6 | $92 |
| Sanofi-aventis U.S. LLC | 6 | $85 |
| Kowa Pharmaceuticals America, Inc. | 3 | $71 |
| Amarin Pharma, Inc. | 4 | $67 |
| Novartis | 4 | $65 |
| Si-bone, Inc. | 2 | $60 |
| AbbVie | 2 | $48 |
| Johnson & Johnson | 2 | $47 |
| Boston Scientific | 1 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| GSK | 2 | $34 |
| Hologic Sales And Service, LLC | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Edwards Lifesciences | 1 | $30 |
| TMS Neurohealth Centers Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Novo Nordisk | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $15 |
| Seqirus USA Inc | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $12 |
How this compares
$2,315 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 116 | $120,068 |
| TrulicityDulaglutide | 64 | $64,885 |
| OzempicSemaglutide | 42 | $50,868 |
| MounjaroTirzepatide | 45 | $48,210 |
| EliquisApixaban | 41 | $34,705 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $19,087 |
| MyrbetriqMirabegron | 12 | $9,898 |
| TradjentaLinagliptin | 12 | $6,002 |
| Rosuvastatin Calcium | 261 | $4,847 |
| Atorvastatin Calcium | 244 | $3,100 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $2,547 |
| Levothyroxine Sodium | 149 | $2,144 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $2,104 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 24 | $1,860 |
| Potassium Chloride | 83 | $1,648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $131 | $126,070128 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $256 | $113,095109 claims |
| Novo NordiskOzempic | $18 | $50,86842 claims |
| PfizerEliquis | $92 | $34,70541 claims |
| AstraZenecaBreztri Aerosphere | $510 | $19,08728 claims |
| AbbVieSynthroid | $48 | $1,01025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Oceanside
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.